Formulation Development and Evaluation of Deferasirox dispersible tablets

Abstract

Formulation development and evaluation of Deferasirox dispersible tablets focuses on designing a patient-friendly, orally administrable dosage form that ensures rapid dispersion, enhanced palatability, and consistent bioavailability. Deferasirox, a poorly water-soluble iron-chelating agent, requires formulation strategies such as the use of suitable superdisintegrants, wet granulation techniques, and solubilizing agents to improve its dissolution profile. The development process typically involves optimization of tablet hardness, friability, disintegration time, and uniformity of drug content to achieve robust mechanical strength while maintaining fast dispersion in water. Evaluation studies further include in-vitro dissolution testing, compatibility assessments, and stability studies to ensure long-term product performance. Overall, well-designed Deferasirox dispersible tablets provide an effective and convenient therapeutic option for pediatric and geriatric patients requiring chronic iron chelation therapy. The objective of the current study was to development optimize a oral disintegration tablets. Deferasirox is a rationally designed oral Iron chelator.